Peter Hino is a Dermatology physician. OpenAlex indexes 9 publications with 342 citations (h-index 6); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8230 Walnut Hill Ln
Suite 500
Dallas, TX 752314482
Telephone
214-739-5821Provider last certified this registry record 10 Feb 2022.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202510 payments
- Galderma Laboratories, L.P.Program year202514 payments
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year202511 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
35.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.3%Valacyclovir100%Part D≥30 patientsAzole Antifungal8.9%Ketoconazole100%Part D≥27 patients+ 3 more classes in this area
Sensory organs
32.4%Corticosteroid32.4%Clobetasol Propionate79%Desonide13%Betamethasone Dipropionate8%Part D≥107 patientsDermatology
13.5%Corticosteroid13.5%Triamcinolone Acetonide81%Halobetasol Propionate19%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy of Trifecting<sup>®</sup> Night Cream, a Novel Triple acting Skin Brightening Product: A Double-blind, Placebo-controlled Clinical Study.
PubMed
2018 - A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating an Oral Anti-aging Skin Care Supplement for Treating Photodamaged Skin.
PubMed
2016 - Development and Clinical Assessment of a Comprehensive Product for Pigmentation Control in Multiple Ethnic Populations.
PubMed
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”